Today in America with Terry Bradshaw to feature Attana
Today in America with Terry Bradshaw is pleased to announce that Attana will be featured in an upcoming segment on topics, trends, and issues related to "Improving Diagnostic Outcomes through Bionsensor Technology" as part of the show's "Medical Minutes" series.
- (1888PressRelease) February 19, 2011 - Coral Springs FL - The Producers of Today in America with Terry Bradshaw are pleased to announce that Attana will be featured in an upcoming segment on topics, trends, and issues related to "Improving Diagnostic Outcomes through Bionsensor Technology" as part of the show's "Medical Minutes" series.
The complexities of the human body, combined with incessant government regulation, make researching and developing new pharmaceuticals an extremely expensive venture. Not only does the need for funding augment with each step of the process, the cost of abandoning a project at any point becomes exponentially devastating. In an economy where funding is scarce and investors are exceedingly cautious about committing resources, there has never been a greater need for the ability to identify early on which new pharmaceutical products would likely be viable candidates, and which ones would not. Fortunately, Swedish company Attana has developed a line of biosensors that can make testing much more accurate and comprehensive by detecting finer and subtler characteristics of how biomolecules react to pharmaceutical agents.
Based in Stockholm, Sweden, Attana was founded in 2002 by Teodor Aastrup, who dreamed of creating a tool capable of measuring biological interactions exactly as the actual events in the human body. After developing the company's first instrument, the Attana 80, Teodor would strap the instrument to his bicycle and travel to local universities to give demonstrations. There, scientists were met with disbelief by the potential of the technology. Teodor had a hunch he was on to something, and decided to name his burgeoning company "Attana" after the Swedish verb "att ana", which means "to sense or to have a hunch". Today, the company remains steadfast in its mission to provide the life science community with biologically relevant information to increase success during clinical trials.
"The Attana biosensors can examine far more complex interactions than ever before-reaching right to the surface of the cell," says CEO and Founder Teodor Aastrup. "This vital information can be made available far earlier in the testing process-even before costly animal and human trials get underway."
The five minute segment will educate viewers on the rising costs of testing new pharmaceuticals, the mechanics of the research and development behind it, and how Attana's revolutionary technology combines both efforts at a significantly lower cost. For more information, please visit www.attana.com